TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Mar 31, 2021 21:18 JST
Source:
Eisai
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
TOKYO, Mar 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA (generic name: lenvatinib mesylate), in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s KEYTRUDA (generic name: pembrolizumab) as a treatment for patients with advanced renal cell carcinoma (RCC). This is the first application to be submitted in Japan for this combination therapy.
This application is based on the results of the Phase 3 CLEAR study (Study 307/KEYNOTE-581) for the first-line treatment of patients with advanced RCC, which were presented at the 2021 Genitourinary Cancers Symposium (ASCO GU), and simultaneously published in the New England Journal of Medicine in February 2021. In this trial, LENVIMA plus KEYTRUDA demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of progression-free survival (PFS) as well as key secondary endpoints of overall survival (OS) and objective response rate (ORR) versus sunitinib. The safety profile of LENVIMA plus KEYTRUDA was consistent with previously reported studies.
Worldwide, it is estimated that there were more than 430,000 new cases of kidney cancer diagnosed and nearly 180,000 deaths from the disease in 2020.1 In Japan, there were more than 25,000 new cases and 8,000 deaths in 2020.2 RCC is by far the most common type of kidney cancer; about nine out of 10 kidney cancers are RCC.3 Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases. Approximately 30% of patients with RCC will have metastatic disease at diagnosis, and as many as 40% will develop metastases after primary surgical treatment for localized RCC.4,5 Survival is highly dependent on the stage at diagnosis, and with a five-year survival rate of 12% for metastatic disease, the prognosis for these patients is poor.6
Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of contribution by LENVIMA and KEYTRUDA to patients with cancer.
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
More Press release >>
Latest Press Release
Mitsubishi Motors to Launch All-New Eclipse Sportback EV in the United States and Canada
Jun 10, 2026 23:15 JST
Bosch Home Comfort Group and Hitachi Group agree to collaborate on Intelligent connectivity and diagnosis solutions for Commercial Air Conditioning based on "HMAX for Buildings"
Jun 10, 2026 22:47 JST
Hitachi and Google Cloud expand strategic alliance to accelerate real-world deployment of physical AI through FDE and advanced cybersecurity solutions
Jun 10, 2026 22:18 JST
Toyota to participate in the "1000 Miglia Gran Turismo Experience 2026," a special program of the historic Italian rally, the 1000 Miglia
Jun 10, 2026 21:39 JST
Mazda Advances Toward Commercialization of Onboard CO2 Capture System
Jun 09, 2026 00:03 JST
Collaboration Between OCTARVIA Programs and MiPoLin(R)
Jun 08, 2026 23:34 JST
Hitachi joins Anthropic's "Project Glasswing" an AI-powered security program
Jun 08, 2026 23:04 JST
Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries
Jun 08, 2026 22:38 JST
Island States Ocean Summit Concludes Launch of the "OCEAN STATES INITIATIVE"
Jun 08, 2026 14:00 JST
Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates
Jun 04, 2026 23:49 JST
Fujitsu and Daiichi Life Group Launch Joint Research to Advance Asset Management with Quantum Technology
Jun 04, 2026 23:17 JST
"Making Children and Adults Smile:" Honda Launches the SMILE RIDER PROJECT
Jun 04, 2026 22:46 JST
GR Premiers GRMN Corolla
Jun 04, 2026 22:05 JST
Island States Ocean Summit Opens in Tokyo
Jun 04, 2026 12:00 JST
Mazda and Nippon Express Launch Demonstration Trial Using Biodiesel Fuel
Jun 04, 2026 00:26 JST
NEC Wins at the Newsweek AI Impact Awards 2026
Jun 04, 2026 00:09 JST
Mitsubishi Heavy Industries and Preferred Networks Form Business Alliance to Jointly Develop Japan-Made AI Technologies for Mission-Critical Applications
Jun 03, 2026 23:51 JST
JAL Engineering and Mitsubishi Heavy Industries Establish Joint Venture "Aero Breath" for Aircraft Aftermarket Business
Jun 03, 2026 23:27 JST
MHI Receives Waste Treatment Technology Verification Report from JESC for Its Biomass High-Efficiency Recovery and Recycling System AdBio
Jun 03, 2026 23:02 JST
DUNLOP and Fujitsu Reduce Tire Structural Analysis Time by Approximately 90% Using AI
Jun 03, 2026 22:31 JST
More Latest Release >>